Endocrine drugs

This Annual Review is dedicated to updated information on endocrine drugs. The following table lists 134 drugs under development in this area, some of which have been published in previous issues of the journal and others that have been marketed for an indication other than that discussed in the review.. Information on the following 13 products is updated here: alprostadil, AS-3201, etonogestrel, examorelin, fidarestat, mitiglinide calcium hydrate, NBI-6024, netoglitazone, NN-2211, pegvisomant, pramlintide acetate, raxofelast and reglitazar. Once again, we remind our readers that all of the information presented in this Review is available in electronic format in our drug discovery portal Integrity.